Rapt Therapeutics Inc

General ticker "RAPT" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $40.4M

Rapt Therapeutics Inc does not follow the US Stock Market performance with the rate: -35.2%.

Estimated limits based on current volatility of 25.9%: low 0.92$, high 1.57$

Factors to consider:

  • Current price 87.1% below estimated low
  • Earnings for 9 months up through Q3 are close to our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [13.52$, 30.38$]
  • 2024-12-30 to 2025-12-30 estimated range: [14.65$, 31.90$]

Financial Metrics affecting the RAPT estimates:

  • Negative: Non-GAAP EPS, $ of -3.04 <= 0.10
  • Negative: Operating profit margin, % of -100 <= 1.03
  • Negative: Operating cash flow per share per price, % of -12.12 <= 2.35
  • Negative: negative Net income
  • Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
  • Negative: Industry earnings per price (median), % of -26.04 <= 1.31

Similar symbols

Short-term RAPT quotes

Long-term RAPT plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $3.81MM $1.53MM $0.00MM
Operating Expenses $73.02MM $87.32MM $127.06MM
Operating Income $-69.21MM $-85.80MM $-127.06MM
Non-Operating Income $0.01MM $1.96MM $10.26MM
R&D Expense $56.98MM $67.08MM $101.00MM
Income(Loss) $-69.20MM $-83.84MM $-116.80MM
Profit(Loss) $-69.20MM $-83.84MM $-116.80MM
Stockholders Equity $186.38MM $245.17MM $147.03MM
Assets $198.64MM $266.21MM $173.33MM
Operating Cash Flow $-61.03MM $-70.77MM $-97.05MM
Capital expenditure $0.76MM $0.84MM $1.12MM
Investing Cash Flow $-81.35MM $-45.49MM $104.13MM
Financing Cash Flow $141.48MM $131.18MM $1.45MM
Earnings Per Share* $-2.49 $-2.52 $-3.05

* EPS are Split Adjusted, recent splits may be reflected with a delay.